Trend
DailyUptrend (starting)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bullish
Daily trend turns down below $3.35
Key levels
Resistance$5.00
Resistance$4.37
Support$3.83
Support$3.35
Latest news & SEC filings
No headlines in the last 90 days.
Annexon is a drug developer focused on therapies that block the classical complement pathway to treat inflammatory conditions of the nervous system, retina, and other tissues. Its lead candidates include tanruprubart for Guillain-Barré syndrome, vonaprument for the dry form of macular degeneration marked by geographic atrophy, and ANX1502, an oral candidate for autoimmune disease. The company owns rights to develop and sell its candidates globally and has operations in the United States and Europe.
Based on the company's 10-K filed Mar 30, 2026.
Nasdaq · Healthcare
SEPT Low Target
$3.00
SEPT Mid Target
$15.00
SEPT High Target
$25.00
Analyst Consensus
$15.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ANNX.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$11.85
10
Moat Score
NONE
1/9
Piotroski Score
-0.4
Altman Z-Score
Insider Signal
NEUTRAL
5 buys / 8 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Love Douglas | director officer | Buy | 26,065 | $100K | Sep 24, 2026 |
| Yednock Ted | officer | Buy | 30,646 | $57K | Jun 11, 2026 |
| Satter Muneer A | director | Buy | 613,497 | $3.3M | May 28, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-32.67%
FCF Growth YoY
-58.0%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for ANNX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:01:07 | $3.92 | 1,478 | $$6K | SELL |
| 21:00:25 | $3.92 | 19,232 | $$75K | SELL |
| 20:59:59 | $3.93 | 1,249 | $$5K | BUY |
| 20:59:08 | $3.92 | 1,100 | $$4K | MIDPOINT |
| 20:59:03 | $3.92 | 1,000 | $$4K | MIDPOINT |
5 dark pool trades shown · $$94K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT Investing provides real-time options flow tracking for ANNX, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $4 | Dec 18 | 35 | $$20.2K | 200 | BLOCK |
| CALL | $4 | Dec 18 | 35 | $$24.4K | 200 | BLOCK |
| CALL | $5 | Dec 18 | 35 | $$4370 | 46 | SWEEP |
| CALL | $5 | Jan 15 | 63 | $$3565 | 23 | SWEEP |
| CALL | $5 | Jan 15 | 63 | $$775 | 5 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Annexon, Inc. (ANNX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Annexon, Inc. (ANNX) is at $3.92, down 1.26% (-$0.05) at the Nov 13, 2026 close.
Annexon shares surged 9.86% to close at $4.01 after HC Wainwright raised its price target to $25 from $14 while maintaining a Buy rating. The stock traded as high as $4.03 on heavy volume of over 6.1 million shares, well above its open of $3.65.
The average analyst price target for ANNX is $15.00, ranging from $3 to $25, based on 5 analysts. Latest: HC Wainwright & Co. maintains on Oct 19, 2026.
Analyst ratings for ANNX: 0 Buy, 6 Hold, 1 Sell — consensus Hold.
ANNX last reported on Aug 12, 2026: EPS -$0.28 vs -$0.24 expected — a miss of 17.3%.
ANNX does not currently pay a dividend.
Support: $3.83, $3.35, $3.03. Resistance: $4.37, $5.00, $5.28.
Insider activity: NEUTRAL, 5 buys and 8 sells in the last 90 days.